



Formulary Update

MANITOBA

Teva Canada is pleased to announce that the following products will be listed in the Part 3 Exception Drug Status Program effective January 21, 2021.

Product Name	Strength	Size	Item Number	DIN
TEVA-EVEROLIMUS	2.5 mg	30, Blister	72100-0127	02463229
TEVA-EVEROLIMUS	5 mg	30, Blister	72101-0127	02463237
TEVA-EVEROLIMUS	10 mg	30, Blister	72103-0127	02463253